Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping

Clinical Pharmacology and Therapeutics

Volumn 72, Issue 6, 2002, Pages 718-728

  Lee, Jang Ik ^a,b,c,d   Chaves Gnecco, Diego ^a,b,c,d   Amico, Janet A ^a,b,c,d   Kroboth, Patricia D ^a,b,c,d   Wilson, John W ^a,b,c,d   Frye, Reginald F ^a,b,c,d  

^a Universigy of Pittsburgh   (United States)

^b SCHOOL OF MEDICINE   (United States)

^c GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A; FLURAZEPAM; KETOCONAZOLE; MIDAZOLAM; ORAL CONTRACEPTIVE AGENT; PARACETAMOL; PHENOTHIAZINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DATA ANALYSIS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBSTRATE; EXTRACTION; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; INTERMETHOD COMPARISON; INTESTINE; LIVER; LIVER METABOLISM; MALE; NONLINEAR REGRESSION ANALYSIS; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTI-ANXIETY AGENTS; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; BIOLOGICAL AVAILABILITY; BIOLOGICAL MARKERS; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP3A; DRUG ADMINISTRATION SCHEDULE; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; INFUSIONS, INTRAVENOUS; INTESTINES; KETOCONAZOLE; LIVER; MALE; MIDAZOLAM; MIDDLE AGED; OXIDOREDUCTASES, N-DEMETHYLATING; PHENOTYPE; REFERENCE VALUES;

EID: 0036908935     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2002.129068     Document Type: Article

References (42)

1. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270:414-23.
2. Watkins PB, Wrighton SA, Schuetz EG, Molowa DT, Guzelian PS. Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J Clin Invest 1987;80:1029-36.
3. Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 1997;32:210-58.
4. Wacher VJ, Silverman JA, Zhang Y, Benet LZ. Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J Pharm Sci 1998;87:1322-30.
5. Wrighton SA, Stevens JC. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 1992;22:1-21.
6. Lown KS, Kolars JC, Thummel KE, Barnett JL, Kunze KL, Wrighton SA, et al. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test. Drug Metab Dispos 1994;22:947-55.
7. Thummel KE, OShea D, Paine MF, Shen DD, Kunze KL, Perkins JD, et al. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 1996;59: 491-502.
8. Thummel KE, Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 1998;38:389-430.
9. Kahan BD, Grevel J. Optimization of cyclosporine therapy in renal transplantation by a pharmacokinetic strategy. Transplantation 1988;46:631-44.
10. Wu CY, Benet LZ, Hebert MF, Gupta SK, Rowland M, Gomez DY, et al. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: Studies with cyclosporine. Clin Pharmacol Ther 1995;58:492-7.
11. Kupferschmidt HH, Ha HR, Ziegler WH, Meier PJ, Krahenbuhl S. Interaction between grapefruit juice and midazolam in humans. Clin Pharmacol Ther 1995;58:20-8.
12. Ducharme MP, Warbasse LH, Edwards DJ. Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin Pharmacol Ther 1995;57:485-91.
13. Krecic-Shepard ME, Barnas CR, Slimko J, Gorski JC, Wainer IW, Schwartz JB. In vivo comparison of putative probes of CYP3A4/5 activity: Erythromycin, dextromethorphan, and verapamil. Clin Pharmacol Ther 1999; 66:40-50.
14. Kharasch ED, Russell M, Mautz D, Thummel KE, Kunze KL, Bowdle A, et al. The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions. Anesthesiology 1997;87:36-50.
15. Kivisto KT, Kroemer HK. Use of probe drugs as predictors of drug metabolism in humans. J Clin Pharmacol 1997;37:S40-8.
16. Watkins PB. Noninvasive tests of CYP3A enzymes. Pharmacogenetics 1994;4:171-84.
17. Gorski JC, Jones DR, Haehner-Daniels BD, Hamman MA, O'Mara EM Jr, Hall SD. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin Pharmacol Ther 1998; 64:133-43.
18. Gorski JC, Hall SD, Jones DR, VandenBranden M, Wrighton SA. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 1994;47:1643-53.
19. Wandel C, Bocker R, Bohrer H, Browne A, Rugheimer E, Martin E. Midazolam is metabolized by at least three different cytochrome P450 enzymes. Br J Anaesth 1994; 73:658-61.
20. Schmiedlin-Ren P, Thummel KE, Fisher JM, Paine MF, Lown KS, Watkins PB. Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of lalpha,25-dihydroxyvitamin D3. Mol Pharmacol 1997; 51:741-54.
21. Tsunoda SM, Velez RL, von Moltke LL, Greenblatt DJ. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: Effect of ketoconazole. Clin Pharmacol Ther 1999;66: 461-71.
22. Wolen RL. The application of stable isotopes to studies of drug bioavailability and bioequivalence. J Clin Pharmacol 1986;26:419-24.
23. Van Langenhove A. Isotope effects: Definitions and consequences for pharmacologic studies. J Clin Pharmacol 1986;26:383-9.
24. Karlsson MO, Bredberg U. Estimation of bioavailability on a single occasion after semisimultaneous drug administration. Pharmaceut Res 1989;6:817-21.
25. Meijer BA, Ceyssens KG, de Jong WT, de Greve BI. Bioavailability of flumequine after semisimultaneous administration to veal calves. Pharmaceut Res 1994;11: 117-21.
26. Bredberg U, Karlsson MO, Borgstrom L. A comparison between the semisimultaneous and the stable isotope techniques for bioavailability estimation of terbutaline in humans. Clin Pharmacol Ther 1992;52:239-48.
27. Karlsson MO, Lindberg-Freijs A. Comparison of methods to calculate cyclosporine A bioavailability from consecutive oral and intravenous doses. J Pharmacokinet Biopharm 1990;18:293-311.
28. Kharasch ED, Mautz D, Senn T, Lentz G, Cox K. Menstrual cycle variability in midazolam pharmacokinetics. J Clin Pharmacol 1999;39:275-80.
29. Kroboth PD, Folan MM, Lush RM, Chaikin PC, Shukla UA, Barbhaiya R, et al. Coadministration of nefazodone and benzodiazepines: I. Pharmacodynamic assessment. J Clin Psychopharmacol 1995;15:306-19.
30. Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Hartwell PS, et al. Use of midazolam as a human cytochrome P450 3A probe: I. In vitro in vivo correlation in liver transplant patients. J Pharmacol Exp Ther 1994; 271:549-56.
31. Yuen KH, Peh KK. Simple high-performance liquid chromatographic method for determination of ketoconazole in human plasma. J Chromatogr B Biomed Sci Appl 1998;715:436-40.
32. Smith MT, Eadie MJ, Brophy TO. The pharmacokinetics of midazolam in man. Eur J Clin Pharmacol 1981;19: 271-8.
33. Greenblatt DJ, Abernethy DR, Locniskar A, Harmatz JS, Limjuco RA, Shader RI. Effect of age, gender, and obesity on midazolam kinetics. Anesthesiology 1984;61:27-35.
34. Wilkinson GR. Clearance approaches in pharmacology. Pharmacol Rev 1987;39:1-47.
35. Wynne HA, Cope LH, Mutch E, Rawlins MD, Wood-house KW, James OF. The effect of age upon liver volume and apparent liver blood flow in healthy man. Hepatology 1989;9:297-301.
36. Gabrielsson J, Weiner D. Semisimultaneous method. In: Gabrielsson J, Weiner D, editors. Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications. Stockholm: Swedish Pharmaceutical Press; 1997. p. 412-8.
37. McCrea J, Prueksaritanont T, Gertz BJ, Carides A, Gillen L, Antonello S, et al. Concurrent administration of the erythromycin breath test (EBT) and oral midazolam as in vivo probes for CYP3A activity. J Clin Pharmacol 1999; 39:1212-20.
38. Olkkola KT, Backman JT, Neuvonen PJ. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994;55:481-5.
39. Daneshmend TK, Warnock DW, Ene MD, Johnson EM, Potten MR, Richardson MD, et al. Influence of food on the pharmacokinetics of ketoconazole. Antimicrob Agents Chemother 1984;25:1-3.
40. von Moltke LL, Greenblatt DJ, Schmider J, Duan SX, Wright CE, Harmatz JS, et al. Midazolam hydroxylation by human liver microsomes in vitro: Inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents. J Clin Pharmacol 1996;36:783-91.
41. Gibbs MA, Thummel KE, Shen DD, Kunze KL. Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: Comparison of K-I values and impact of CYP3A5 expression. Drug Metab Dispos 1999;27:180-7.
42. Tolia V, Brennan S, Aravind MK, Kauffman RE. Pharmacokinetic and pharmacodynamic study of midazolam in children during esophagogastroduodenoscopy. J Pediatr 1991;119:467-71.